Author:
Hassan Ghmkin,Afify Said M.,Zahra Maram H.,Nawara Hend M.,Kumon Kazuki,Iwasaki Yoshiaki,Salomon David S.,Seno Akimasa,Seno Masaharu
Abstract
AbstractInduced pluripotent stem cells (iPSCs) are useful tools for modeling diseases and developing personalized medicine. We have been developing cancer stem cells (CSCs) from iPSCs with conditioned medium (CM) of cancer-derived cells as the mimicry of the microenvironment of tumor initiation. However, the conversion of human iPSCs has not always been efficient with only CM. In this study, human iPSCs reprogrammed from monocytes of healthy volunteers were cultured in a media containing 50% of the CM from human pancreatic cancer derived BxPC3 cells supplemented with a MEK inhibitor (AZD6244) and a GSK-3α/β inhibitor (CHIR99021). The survived cells were assessed for the characteristics of CSCs in vitro and in vivo. As a result, they exhibited CSC phenotypes of self-renewal, differentiation, and malignant tumorigenicity. Primary culture of the malignant tumors of the converted cells exhibited the elevated expression of CSC related genes CD44, CD24 and EPCAM maintaining the expression of stemness genes. In conclusion, the inhibition of GSK-3α/β and MEK and the microenvironment of tumor initiation mimicked by the CM can convert human normal stem cells into CSCs. This study could provide insights into establishing potentially novel personalized cancer models which could help investigate the tumor initiation and screening of personalized therapies on CSCs.
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Clinical Biochemistry,Biomedical Engineering,Bioengineering,Biotechnology
Reference18 articles.
1. Afify SM, Sanchez Calle A, Hassan G, Kumon K, Nawara HM, Zahra MH, Mansour HM, Khayrani AC, Alam MJ, Du J et al (2020) A novel model of liver cancer stem cells developed from induced pluripotent stem cells. Br J Cancer 122:1378–1390. https://doi.org/10.1038/s41416-020-0792-z
2. Bayik D, Lathia JD (2021) Cancer stem cell-immune cell crosstalk in tumour progression. Nat Rev Cancer. https://doi.org/10.1038/s41568-021-00366-w
3. Beatty GL, Gladney WL (2015) Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res 21:687–692. https://doi.org/10.1158/1078-0432.CCR-14-1860
4. Calle AS, Nair N, Oo AK, Prieto-Vila M, Koga M, Khayrani AC, Hussein M, Hurley L, Vaidyanath A, Seno A et al (2016) A new PDAC mouse model originated from iPSCs-converted pancreatic cancer stem cells (CSCcm). Am J Cancer Res 6:2799–2815
5. Chao HM, Chern E (2018) Patient-derived induced pluripotent stem cells for models of cancer and cancer stem cell research. J Formos Med Assoc 117:1046–1057. https://doi.org/10.1016/j.jfma.2018.06.013